Skip to main content

Advertisement

Log in

Management of Chronic Bacterial Prostatitis

  • Surgery (M Desai, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We conducted a review of the literature describing the most up-to-date diagnosis and treatment options of chronic bacterial prostatitis.

Recent Findings

Recurrence after oral antimicrobial therapy is common, due in part to the rising rates of antimicrobial resistance and inability to completely clear the offending bacteria from the prostate following prostatitis. Recent literature has described various treatment options for chronic bacterial prostatitis refractory to conventional antimicrobial agents, including the use of alternative agents such as fosfomycin, direct antimicrobial injections into the prostate, surgical removal of infected prostatic tissue, chronic oral antibiotic suppression, and an emerging novel therapy utilizing bacteriophages to target antibiotic resistant bacteria.

Summary

Management of chronic bacterial prostatitis, especially recurrence after oral antimicrobial treatment, remains challenging. This review highlights an urgent need for further evidence assessing the efficacy and safety of treatment modalities for chronic bacterial prostatitis refractory to conventional oral antimicrobials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis [5]. J Am Med Assoc. 1999;282:236–7.

    Article  CAS  Google Scholar 

  2. Sharp VJ, Takacs EB. Prostatitis: diagnosis and treatment. Am Fam Phys. 2010.

  3. Prostatitis NJ, Conditions R. Orchitis, and Epididymitis. In: Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell-Walsh Urol. Philadelphia: Saunders; 2012. p. 327–56.

    Google Scholar 

  4. McNaughton Collins M, Stafford RS, O’Leary MP, Barry MJ. Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a National Survey of physician visits. Urology. 1999;53(5):921–5.

    Article  Google Scholar 

  5. Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of Prostatitis. Int J Antimicrob Agents. 2008.

  6. Collins MMN, Stafford RS, O’Leary MP, Barry MJ. How common is prostatitis? A National Survey of Physician Visits. J Urol. 1998.

  7. De La Rosette JJMCH, Hubregtse MR, Meuleman EJH, Stolk-engelaar MVM, Debruyne FMJ. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology. 1993.

  8. Yoon B Il, Kim S, Han DS, Ha US, Lee SJ, Kim HW, Han CH, Cho YH. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother. 2012.

  9. Nickel J, Downey J, Johnston B, Clark J. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol. 2004;165(5):1539–44.

    Article  Google Scholar 

  10. Schneider H, Ludwig M, Hossain HM, Diemer T, Weidner W. The 2001 Giessen cohort study on patients with Prostatitis syndrome - an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia. 2003;35(5):258–62.

    CAS  PubMed  Google Scholar 

  11. Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord. 2002;40(10):536–41.

    Article  CAS  PubMed  Google Scholar 

  12. Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology. 2011;78(3):511–4.

    Article  PubMed  Google Scholar 

  13. Özden E, Bostanci Y, Yakupoglu KY, Akdeniz E, Yilmaz AF, Tulek N, et al. Incidence of acute prostatitis caused by extended-Spectrum β-lactamase-producing Escherichia Coli after transrectal prostate biopsy. Urology. 2009;74(1):119–23.

    Article  PubMed  Google Scholar 

  14. Wolf JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179(4):1379–90.

    Article  PubMed  Google Scholar 

  15. Kim JW, Oh MM, Bae JH, Kang SH, Park HS, Moon DG. Clinical and microbiological characteristics of spontaneous acute prostatitis and transrectal prostate biopsy-related acute prostatitis: Is transrectal prostate biopsy-related acute prostatitis a distinct acute Prostatitis category? J Infect Chemother. 2015;21(6):434–7.

    Article  PubMed  Google Scholar 

  16. Breyer BN, Van Den Eeden SK, Horberg MA, Eisenberg ML, Deng DY, Smith JF, et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol. 2011;185(5):1710–5.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Schaeffer AJ. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 2006;355:1690–8.

    Article  CAS  PubMed  Google Scholar 

  18. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50(12):1641–52.

    Article  PubMed  Google Scholar 

  19. Cornia PB, Takahashi TA, Lipsky BA. The microbiology of Bacteriuria in men: a 5-year study at a veterans’ affairs hospital. Diagn Microbiol Infect Dis. 2006;56:25–30.

    Article  PubMed  Google Scholar 

  20. Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology. 2005;66(4):721–5.

    Article  PubMed  Google Scholar 

  22. Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199(1):161–71.

    Article  PubMed  Google Scholar 

  23. Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, et al. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol. 2006;175(5):1937–42.

    Article  PubMed  Google Scholar 

  24. Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Cole SR, De Marzo AM, et al. Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration. Br J Cancer. 2011;105(5):602–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Larsen RA, Bozzette S, McCutchan JA, Chiu J, Leal MA, Richman DD. Persistent Cryptococcus Neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med. 1989;111(2):125–8.

    Article  CAS  PubMed  Google Scholar 

  26. McNaughton Collins M, Fowler FJ, Elliott DB, Albertsen PC, Barry MJ. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test? Urology. 2000;55(3):403–7.

    Article  CAS  PubMed  Google Scholar 

  27. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE, Zeitlin S, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol. 2006;176(1):119–24.

    Article  PubMed  Google Scholar 

  28. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003;49(6):269–79.

    Article  CAS  PubMed  Google Scholar 

  29. Aagaard J, Madsen PO. Bacterial prostatitis: new methods of treatment. Urology. 1991;37(3 Suppl):4–8.

    Article  CAS  PubMed  Google Scholar 

  30. Perletti G, Skerk V, Magri V, Markotic A, Mazzoli S, Parnham MJ, et al. Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique Pharmacokinetic and Pharmacodynamic profile (review). Mol Med Rep. 2011;4:1035–44.

    CAS  PubMed  Google Scholar 

  31. Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et al. Is Fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–5.

    Article  CAS  PubMed  Google Scholar 

  32. Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, et al. Penetration of Piperacillin-Tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics. J Infect Chemother. 2015;21(8):575–80.

    Article  CAS  PubMed  Google Scholar 

  33. Bonkat G, Pickard R, Bartoletti R, Cai T, Bruyère F, Geerlings S, Köves B, Wagenlehner F. EAU guidelines on urological infections. Eur Assoc Urol. 2018.

  34. Perletti G, Marras E, Wagenlehner FME, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013;12(8):CD009071.

    Google Scholar 

  35. Busetto GM, Giovannone R, Ferro M, Tricarico S, Del Giudice F, Matei DV, et al. Chronic bacterial Prostatitis: efficacy of short-lasting antibiotic therapy with Prulifloxacin (Unidrox®) in association with saw palmetto extract, Lactobacillus Sporogens and Arbutin (Lactorepens®). BMC Urol. 2014;14:53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB. Safety and efficacy of levofloxacin 750mg for 2 weeks or 3 weeks compared with levofloxacin 500mg for 4 weeks in treating chronic bacterial Prostatitis. Curr Med Res Opin. 2010;26(6):1433–41.

    Article  CAS  PubMed  Google Scholar 

  37. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, et al. Antibiotic resistance in Escherichia Coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006;27(6):468–75.

    Article  CAS  PubMed  Google Scholar 

  38. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia Coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob. Agents Chemother. 2012;56(4):2181–3.

    Article  CAS  Google Scholar 

  39. Swami SK, Liesinger JT, Shah N, Baddour LM, Banerjee R. Incidence of antibiotic-resistant Escherichia Coli Bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clin Proc. 2012;87(8):753–9.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Denisuik AJ, Lagacé-Wiens PRS, Pitout JD, Mulvey MR, Simner PJ, Tailor F, et al. Canadian antimicrobial resistance Alliance. Molecular epidemiology of extended-Spectrum β-lactamase-, AmpC β-lactamase- and Carbapenemase-producing Escherichia Coli and Klebsiella Pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother. 2013;68(Suppl 1):i57–65.

    Article  CAS  PubMed  Google Scholar 

  41. Kandil H, Cramp E, Vaghela T. Trends in antibiotic resistance in urologic practice. Eur Urol Focus. 2016;2(4):363–73.

    Article  PubMed  Google Scholar 

  42. Zhanel GG, Zhanel MA, Karlowsky JA. Oral Fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by multidrug-resistant Escherichia Coli. Can J Infect Dis Med Microbiol. 2018;2018:1–9.

    Google Scholar 

  43. Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D, et al. Oral Fosfomycin for the treatment of chronic bacterial Prostatitis. J Antimicrob Chemother. 2019;74:1430–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Demonchy E, Courjon J, Ughetto E, Durand M, Risso K, Garraffo R, et al. Cefoxitin-based antibiotic therapy for extended-Spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study. Int J Antimicrob Agents. 2018;51(6):836–41.

    Article  CAS  PubMed  Google Scholar 

  45. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. CDC - MMWR Recomm Rep. 2015;64(RR-03):1–137.

    PubMed  Google Scholar 

  46. Gill BC, Shoskes DA. Bacterial Prostatitis. Curr Opin Infect Dis. 2016;29(1):86–91.

    Article  PubMed  Google Scholar 

  47. Bartoletti R, Cai T, Nesi G, Albanese S, Meacci F, Mazzoli S, et al. The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study. World J Urol. 2014;32(3):737–42.

    Article  CAS  PubMed  Google Scholar 

  48. Park MG, Cho MC, Cho SY, Lee JW. Clinical and microbiological features and factors associated with fluoroquinolone resistance in men with community-acquired acute bacterial prostatitis. Urol Int. 2016;96(4):443–8.

    Article  CAS  PubMed  Google Scholar 

  49. Zhao WP, Li YT, Chen J, Zhang ZG, Jiang H, Xia D, et al. Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis. Asian J Androl. 2012;14(5):715–9.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Wagenlehner FME, Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Clin Microbiol Infect. 2006;12(s3):67–80.

    Article  CAS  PubMed  Google Scholar 

  51. Nickel JC, Costerton JW. Bacterial localization in antibiotic-refractory chronic bacterial prostatitis. Prostate. 1993;23(2):107–14.

    Article  CAS  PubMed  Google Scholar 

  52. Soto SM, Smithson A, Martinez JA, Horcajada JP, Mensa J, Vila J. Biofilm formation in uropathogenic Escherichia Coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance. J Urol. 2007;177(1):365–8.

    Article  CAS  PubMed  Google Scholar 

  53. Mazzoli S. Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications. FEMS Immunol Med Microbiol. 2010;59(3):337–44.

    Article  CAS  PubMed  Google Scholar 

  54. Park SH, Ryu JK, Choo GY, Chung YG, Seong DH, Kim CH, et al. Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis. Int J Urol. 2015;22(5):508–12.

    Article  PubMed  Google Scholar 

  55. Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Fernández-Hidalgo N, Andreu A, Larrosa N, et al. Long-term Fosfomycin-Tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis. Antimicrob Agents Chemother. 2016;60(3):1854–8.

    Article  CAS  PubMed Central  Google Scholar 

  56. Magri V, Montanari E, Škerk V, Markotić A, Marras E, Restelli A, et al. Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androl. 2011;13(6):819–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Chou YH, Tiu CM, Liu JY, Chen JD, Chiou HJ, Chiou SY, et al. Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound Med Biol. 2004;30(6):719–24.

    Article  PubMed  Google Scholar 

  58. Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, et al. Comprehensive overview of prostatitis. Biomed Pharmacother. 2017;94:1064–76.

    Article  PubMed  Google Scholar 

  59. Bowen D, Dielubanza E, Schaeffer A. Chronic bacterial prostatitis and chronic pelvic pain syndrome. BMJ Clin Evid. 2015;1802.

  60. Lee BSB, Bhuta T, Simpson JM, Craig JC. Methenamine Hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD003265.

    PubMed  Google Scholar 

  61. Hu WL, Zhong SZ, He HX. Treatment of chronic bacterial prostatitis with Amikacin through anal submucosal injection. Asian J Androl. 2002;4(3):163–7.

    CAS  PubMed  Google Scholar 

  62. Toth A, Guercini F, Feldthouse D, Zhang J. Injection therapy for chronic prostatitis: a retrospective analysis of 77 cases. Arch Ital Di Urol Androl. 2018;90(1):34–9.

    Article  CAS  Google Scholar 

  63. Barnes R, Hadley H, O’Donoghue E. Transurethral resection of the prostate for chronic bacterial prostatitis. Prostate. 1982;3(3):215–9.

    Article  CAS  PubMed  Google Scholar 

  64. Schoeb D, Schlager D, Boeker M, Wetterauer U, Schoenthaler M, Herrmann T, et al. Surgical therapy of prostatitis: a systematic review. World J Urol. 2017;35(11):1659–68.

    Article  PubMed  Google Scholar 

  65. Letkiewicz S, Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Górskib A. Eradication of Enterococcus faecalis by Phage Therapy in Chronic Bacterial Prostatitis - Case Report. Folia Microbiol (Praha). 2009;54(5):457–61.

    Article  CAS  Google Scholar 

  66. Letkiewicz S, Miedzybrodzki R, Kłak M, Jończyk E, Weber-Dabrowska B, Górski A. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol. 2010;60(2):99–112.

    Article  CAS  PubMed  Google Scholar 

  67. Górski A, Jonczyk-Matysiak E, Lusiak-Szelachowska M, Miedzybrodzki R, Weber-Dabrowska B, Borysowski J, et al. Phage therapy in prostatitis: recent prospects. Front Microbiol. 2018;9:1434.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Delcaru C, Alexandru I, Podgoreanu P, Grosu M, Stavropoulos E, Chifiriuc M, et al. Microbial biofilms in urinary tract infections and prostatitis: etiology, pathogenicity, and combating strategies. Pathogens. 2016;5(4):65.

    Article  PubMed Central  CAS  Google Scholar 

  69. Górski A, Dąbrowska K, Miȩdzybrodzki R, Weber-Dąbrowska B, Łusiak-Szelachowska M, Jończyk-Matysiak E, et al. Phages and immunomodulation. Future Microbiol. 2017;12:905–14.

    Article  CAS  PubMed  Google Scholar 

  70. Nguyen S, Baker K, Padman BS, Patwa R, Dunstan RA, Weston TA, et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. MBio. 2017;8(6).

  71. Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2018;15:11–24.

    Article  PubMed  Google Scholar 

  72. Letkiewicz S, Międzvbrodzki R, Kłak M, Weber Dąbrowska B, Górski A. Pathogen eradication by phage therapy in patients with chronic Bacterial prostatitis. Eur Urol Suppl. 2010;9:140.

    Article  Google Scholar 

  73. Leitner L, Sybesma W, Chanishvili N, Goderdzishvili M, Chkhotua A, Ujmajuridze A, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, Double-Blind Clinical Trial. BMC Urol. 2017;17:90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Zaidi N, Thomas D, Chughtai B. Management of chronic prostatitis (CP). Curr Urol Rep. 2018;19(11):88.

    Article  PubMed  Google Scholar 

  75. Franco JVA, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2019;10(10):CD012552.

    PubMed  Google Scholar 

  76. Holt JD, Garrett WA, McCurry TK, Teichman JMH. Common questions about chronic prostatitis. Am Fam Physician. 2016;93(4):290–6.

    PubMed  Google Scholar 

  77. Franco JVA, Turk T, Jung JH, Xiao YT, Iakhno S, Garrote V, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2019;124(2):197–208.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Amin Sedaghat Herati.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Surgery

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Su, Z.T., Zenilman, J.M., Sfanos, K.S. et al. Management of Chronic Bacterial Prostatitis. Curr Urol Rep 21, 29 (2020). https://doi.org/10.1007/s11934-020-00978-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-020-00978-z

Keywords

Navigation